Dr. Magliocco to Present CAP TODAY Webinar
CAP TODAY / Amgen Webinar
FGFR2b Protein Overexpression: An Emerging IHC-Based Biomarker in G/GEJ Cancer
Date/Time: December 12, 2024, 1PM EST
Location: Virtual Webinar
Sign Up: www.pathlms.com/captodaywebinars/webinars/46021
Why should you register for this webinar?
In the era of precision medicine, biomarkers are emerging to have clinical importance for the diagnosis, treatment, and prognosis of advanced/metastatic G/GEJ cancers.
Join us for a dynamic panel discussion with a multidisciplinary team to:
Review the shift from histology-based to biomarker-driven treatment plans
Understand the prevalence and significance of FGFR2b protein overexpression as an emerging IHC-based biomarker in advanced/metastatic G/GEJ cancer
Discuss how FGFR2b protein overexpression can be detected by IHC
Discuss MDT considerations for optimizing advanced/metastatic G/GEJ cancer diagnostic and biomarker testing workflows
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Presenters: Yan Ji, MD, PhD, MS, Anthony Magliocco, MD, and Shaffer Mok, MD, MBS
What will this webinar empower you to do?
Describe the burden and challenges of advanced/metastatic G/GEJ cancer
Understand the full patient journey from diagnosis to treatment for patients with advanced/metastatic G/GEJ cancer
Recognize the role of FGFR2b protein overexpression as an emerging IHC-based biomarker
Consider optimized diagnostic and testing workflows to support appropriate patient access to biomarker-driven treatment plans for patients with advanced/metastatic G/GEJ cancer
Date/Time: December 12, 2024, 1PM EST | Location: Virtual Webinar
Learn More: www.pathlms.com/captodaywebinars/webinars/46021
For further information, please contact:
Anthony Magliocco MD
CEO & President of Protean BioDiagnostics
Email: info@proteanbiodx.com
Phone: 1 (813) 817 2042
About Protean BioDiagnostics:
Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.
We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.